Adenosine triphosphate (ATP) is actively released in the extracellular environment in
response to tissue damage and cellular stress. Through the activation of P2X and P2Y …

Abstract CD74 (MHC class II invariant chain, Ii) is a non-polymorphic type II transmembrane
glycoprotein. It is clear that, in addition to be an MHC class II chaperone, CD74 has a …

Immunotherapy is rapidly emerging as a cancer treatment with high potential. Recent clinical
trials with anti-CTLA-4 and anti–PD-1/PD-L1 antibodies (mAbs) suggest that targeting …

CD73 generation of immunosuppressive adenosine within the hypoxic tumor
microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor …

CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed
on multiple immune subsets. CD73 also enhances tumor metastasis, although the nature of …

Tumors use several strategies to evade immunosurveillance. One such mechanism is the
generation of adenosine within the tumor microenvironment, which potently suppresses …

SILAC is based on direct addition of selected stable isotope amino acids into the cell culture
medium, allowing superior quantitative analysis of the cellular proteome compared to other …

Extracellular adenosine is a potent immunosuppressor that accumulates during tumor
growth. We performed proof-of-concept studies investigating the therapeutic potential and …

Adenosine targeting is an attractive new approach to cancer treatment, but no clinical study
has yet examined adenosine inhibition in oncology despite the safe clinical profile of …

Despite recognizing the devastating consequences of metastasis, we are not yet able to
effectively treat cancer that has spread to vital organs. The inherent complexity of genomic …